Product Information
RIZATRIPTAN 10 MG ODT is a generic product labeled by Macleods Pharmaceuticals Limited, priced at $0.5097 per EA under NDC 33342009452. Its NADAC has been published 210 times since Sep 28, 2022.
FDA first approved this application on Sep 19, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
10 mg/1
Manufacturer
Macleods Pharmaceuticals LimitedNDC
33342009452
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RIZATRIPTAN BENZOATEApproval Type
Generic (ANDA)
FDA Application
ANDA203146FDA Approved
9/19/2014
TE Code
AB
On Market Since
9/23/2014
Pharmacological Classes
Price Statistics
The NADAC for RIZATRIPTAN 10 MG ODT has been published 210 times since Sep 28, 2022, and over the history we have for it it has declined 28.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5097 per EA |
|---|---|
| All-time high | $0.8390 (Mar 15, 2023) |
| All-time low | $0.4145 (Nov 20, 2024) |
| 52-week high | $0.5620 |
| 52-week low | $0.5097 |
| Median price | $0.5835 |
| Average price | $0.6110 |
| Largest weekly change | -31.5% (Nov 20, 2024) |
| Weeks tracked | 210 |
| Tracking since | Sep 28, 2022 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Macleods Pharmaceuticals Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
rizatriptan benzoate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Serotonin-1b and Serotonin-1d Receptor Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RIZATRIPTAN 10 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for RIZATRIPTAN 10 MG ODT, manufactured by Macleods Pharmaceuticals Limited, is $0.5097 per EA (NDC 33342009452), effective Sep 30, 2026.
How has the price of RIZATRIPTAN 10 MG ODT changed over time?
Over the history we have for it, the NADAC for RIZATRIPTAN 10 MG ODT has declined 28.2%. It has been tracked across 210 weekly CMS publications since Sep 28, 2022.
What are the highest and lowest recorded NADAC prices for RIZATRIPTAN 10 MG ODT?
Since Sep 28, 2022, the NADAC for RIZATRIPTAN 10 MG ODT has ranged from a low of $0.4145 (Nov 20, 2024) to a high of $0.8390 (Mar 15, 2023), with a median of $0.5835 per EA.
Are there cheaper alternatives to RIZATRIPTAN 10 MG ODT?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIZATRIPTAN 10 MG ODT in a comparable dosage form, but none are currently priced below it.
Who manufactures RIZATRIPTAN 10 MG ODT?
RIZATRIPTAN 10 MG ODT (NDC 33342009452) is labeled by Macleods Pharmaceuticals Limited, and CMS classifies it as a generic product.